Delos Capital Partners Overview

  • Investor Type
  • Venture Capital
  • Status
  • Active
  • Professionals
  • 3
Professionals
  • Investments
  • 29
  • Portfolio
  • 19
  • Exits
  • 6
Exits

Delos Capital Partners General Information

Description

Delos Capital Partners is a healthcare-focused fund interested in funding and fostering the growth of science and technology across continents and cultures. The firm is interested in the development of drugs and medical devices that address unmet medical needs and enhance existing therapies by making them safer, improving efficacy and lowering costs. Delos is actively working hand-in-hand with entrepreneurs to bring novel treatments and new devices to market - achieving global success in medicine. The fund's portfolio companies develop solutions in the areas of oncology, gene therapies, neurovascular conditions, infectious diseases, cardiovascular diseases, ophthalmology, orthopedics and metabolic diseases. The firm makes investments through a broad variety of types and transaction structures, including early and late-stage developments, incubation, growth capital, private equity investments, strategic investments, restructurings and recapitalizations and investments in publicly listed securities.

Contact Information

Year Founded
2014
Investor Status
Actively Seeking New Investments
Primary Investor Type
Venture Capital
Other Investor Types
Growth/Expansion
PE/Buyout
Primary Office
  • 19/F, Fung House, 19-20 Connaught Road
  • Central
  • Hong Kong
+852 3912 0000

Delos Capital Partners Investments (29)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
Imperative Care 15-Jul-2021 Later Stage VC 00000 Clinics/Outpatient Services Generating Revenue 00000 0000 00
000000 00000000000 06-May-2021 00000 00000 0000 Drug Discovery Pre-Clinical Trials
000000 00000000000 09-Apr-2021 00000 00000 0000 Drug Discovery Clinical Trials - Phase 2 00000 0000 00
0000.000 31-Mar-2021 00000 00000 Managed Care Stealth 000 0000
000000 00000000000 22-Feb-2021 00000 00000 00000 Biotechnology Clinical Trials - Phase 1 000 0000
00000000 22-Dec-2020 00000 00000 000.00 Pharmaceuticals Generating Revenue 000 0000
0000 00000 19-Oct-2020 00000 00000 Therapeutic Devices Generating Revenue 00000 0000 00
000000 09-Jul-2020 00000 00000 000 Other Devices and Supplies Generating Revenue 00000 0000 00
Clover Biopharmaceuticals 20-May-2020 Later Stage VC 000.00 Biotechnology Clinical Trials - Phase 1 000 0000
Imperative Care 25-Nov-2019 Later Stage VC 0000 Clinics/Outpatient Services Generating Revenue 00000 0000 00
You’re viewing 10 of 29 investments. Get the full list »
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Delos Capital Partners Exits (6)

Company Name Exit Date Exit Type Exit Size
Truvic 15-Jul-2021 Merger/Acquisition
0000 0000000000000 05-Feb-2021 000000000000000000
000000 15-Mar-2018 000000000 00000000
00000 0000000 10-Oct-2017 000000000000000000 00000
Syndax 03-Mar-2016 IPO 000.00
Tanvex Biopharma 13-Aug-2015 IPO
To view Delos Capital Partners’s complete exits history, request access »

Delos Capital Partners Investments by Industry, Year, and Region

Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.

Request a free trial

Delos Capital Partners Team (14)

Name Title Deals Funds Boards Office
Henry Chen JD Co-Founder & Managing Partner 00 0 00 Central, Hong Kong
Lan-Bo Chen Ph.D Venture Partner 0 0 0 Central, Hong Kong
Chi-Chuan Chen Partner 0 Central, Hong Kong
Samuel Yin Ph.D Partner Central, Hong Kong
Tim Xiao Principal 0 0 0 Central, Hong Kong
You’re viewing 5 of 14 team members. Get the full list »